Network analysis of quantitative proteomics on asthmatic bronchi: effects of inhaled glucocorticoid treatment

Respiratory Research

Jan Lötvall³  Elisabet Carlsohn¹  Linda Ekerljung³  Carina Sihlbom¹  Raimundas Sakalauskas²  Kristina Stravinskaite-Bieksiene²  Algirda Krisiukeniene²  Agne Babusyte²  Brigita Sitkauskiene²  Serena E O'Neil³ 

[1] Proteomics Core Facility, Sahlgrenska Academy, University of Gothenburg, Sweden;Department of Pulmonology and Immunology, Lithuanian University of Health Sciences, Lithuania;Krefting Research Centre, Department of Internal Medicine, University of Gothenburg, Sweden

关键词: Ingenuity Pathway Analysis;    isobaric tags for relative and absolute quantitation;    iTRAQ;    network analysis;    glucocorticoid;    bronchial biopsies;    quantitative proteomics;    asthma;   

Others  :  796798
DOI  :  10.1186/1465-9921-12-124

 received in 2011-05-24, accepted in 2011-09-22,  发布年份 2011

【 摘 要 】

Background

Proteomic studies of respiratory disorders have the potential to identify protein biomarkers for diagnosis and disease monitoring. Utilisation of sensitive quantitative proteomic methods creates opportunities to determine individual patient proteomes. The aim of the current study was to determine if quantitative proteomics of bronchial biopsies from asthmatics can distinguish relevant biological functions and whether inhaled glucocorticoid treatment affects these functions.

Methods

Endobronchial biopsies were taken from untreated asthmatic patients (n = 12) and healthy controls (n = 3). Asthmatic patients were randomised to double blind treatment with either placebo or budesonide (800 μg daily for 3 months) and new biopsies were obtained. Proteins extracted from the biopsies were digested and analysed using isobaric tags for relative and absolute quantitation combined with a nanoLC-LTQ Orbitrap mass spectrometer. Spectra obtained were used to identify and quantify proteins. Pathways analysis was performed using Ingenuity Pathway Analysis to identify significant biological pathways in asthma and determine how the expression of these pathways was changed by treatment.

Results

More than 1800 proteins were identified and quantified in the bronchial biopsies of subjects. The pathway analysis revealed acute phase response signalling, cell-to-cell signalling and tissue development associations with proteins expressed in asthmatics compared to controls. The functions and pathways associated with placebo and budesonide treatment showed distinct differences, including the decreased association with acute phase proteins as a result of budesonide treatment compared to placebo.

Conclusions

Proteomic analysis of bronchial biopsy material can be used to identify and quantify proteins using highly sensitive technologies, without the need for pooling of samples from several patients. Distinct pathophysiological features of asthma can be identified using this approach and the expression of these features is changed by inhaled glucocorticoid treatment. Quantitative proteomics may be applied to identify mechanisms of disease that may assist in the accurate and timely diagnosis of asthma.

Trial registration

ClinicalTrials.gov registration NCT01378039

【 授权许可】

   
2011 O'Neil et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Lemanske RF Jr, Busse WW: Asthma: clinical expression and molecular mechanisms. Journal of Allergy and Clinical Immunology 2010, 125:S95-102.
• [2]Masoli M, Fabian D, Holt S, Beasley R: The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004, 59:469-478.
• [3]Rolph MS, Sisavanh M, Liu SM, Mackay CR: Clues to asthma pathogenesis from microarray expression studies. Pharmacology and Therapeutics 2006, 109:284-294.
• [4]Greenlee KJ, Corry DB, Engler DA, Matsunami RK, Tessier P, Cook RG, Werb Z, Kheradmand F: Proteomic identification of in vivo substrates for matrix metalloproteinases 2 and 9 reveals a mechanism for resolution of inflammation. Journal of Immunology 2006, 177:7312-7321.
• [5]Jeong H, Rhim T, Ahn MH, Yoon PO, Kim SH, Chung IY, Uh S, Kim SI, Park CS: Proteomic analysis of differently expressed proteins in a mouse model for allergic asthma. J Korean Med Sci 2005, 20:579-585.
• [6]Wong WS, Zhao J: Proteome analysis of chronically inflamed lungs in a mouse chronic asthma model. International Archives of Allergy and Immunology 2008, 147:179-189.
• [7]Zhang L, Wang M, Kang X, Boontheung P, Li N, Nel AE, Loo JA: Oxidative stress and asthma: proteome analysis of chitinase-like proteins and FIZZ1 in lung tissue and bronchoalveolar lavage fluid. Journal of Proteome Research 2009, 8:1631-1638.
• [8]Larsen K, Malmstrom J, Wildt M, Dahlqvist C, Hansson L, Marko-Varga G, Bjermer L, Scheja A, Westergren-Thorsson G: Functional and phenotypical comparison of myofibroblasts derived from biopsies and bronchoalveolar lavage in mild asthma and scleroderma. Respir Res 2006, 7:11. BioMed Central Full Text
• [9]Gray RD, MacGregor G, Noble D, Imrie M, Dewar M, Boyd AC, Innes JA, Porteous DJ, Greening AP: Sputum proteomics in inflammatory and suppurative respiratory diseases. American Journal of Respiratory and Critical Care Medicine 2008, 178:444-452.
• [10]Wu J, Kobayashi M, Sousa EA, Liu W, Cai J, Goldman SJ, Dorner AJ, Projan SJ, Kavuru MS, Qiu Y, Thomassen MJ: Differential proteomic analysis of bronchoalveolar lavage fluid in asthmatics following segmental antigen challenge. Molecular and Cellular Proteomics 2005, 4:1251-1264.
• [11]Jeong HC, Lee SY, Lee EJ, Jung KH, Kang EH, Kim JH, Park EK, Lee SH, Uhm CS, Cho Y, et al.: Proteomic analysis of peripheral T-lymphocytes in patients with asthma. Chest 2007, 132:489-496.
• [12]Bloemen K, Van Den Heuvel R, Govarts E, Hooyberghs J, Nelen V, Witters E, Desager K, Schoeters G: A new approach to study exhaled proteins as potential biomarkers for asthma. Clin Exp Allergy 2011, 41:346-356.
• [13]Cho WC: Proteomics technologies and challenges. Genomics Proteomics Bioinformatics 2007, 5:77-85.
• [14]Romero R, Kusanovic JP, Gotsch F, Erez O, Vaisbuch E, Mazaki-Tovi S, Moser A, Tam S, Leszyk J, Master SR, et al.: Isobaric labeling and tandem mass spectrometry: a novel approach for profiling and quantifying proteins differentially expressed in amniotic fluid in preterm labor with and without intra-amniotic infection/inflammation. Journal of Maternal-Fetal and Neonatal Medicine 2010, 23:261-280.
• [15]Wang H, Chavali S, Mobini R, Muraro A, Barbon F, Boldrin D, Aberg N, Benson M: A pathway-based approach to find novel markers of local glucocorticoid treatment in intermittent allergic rhinitis. Allergy 2011, 66:132-140.
• [16]Chaerkady R, Letzen B, Renuse S, Sahasrabuddhe NA, Kumar P, All AH, Thakor NV, Delanghe B, Gearhart JD, Pandey A, Kerr CL: Quantitative temporal proteomic analysis of human embryonic stem cell differentiation into oligodendrocyte progenitor cells. Proteomics, in press.
• [17]Dean RA, Overall CM: Proteomics discovery of metalloproteinase substrates in the cellular context by iTRAQ labeling reveals a diverse MMP-2 substrate degradome. Mol Cell Proteomics 2007, 6:611-623.
• [18]Neilson KA, Mariani M, Haynes PA: Quantitative proteomic analysis of cold-responsive proteins in rice. Proteomics 2011, 11:1696-1706.
• [19]Global Strategy for Asthma Management and Prevention NIH publication No 02-3659 Global Initiative for Asthma National Institutes of Health National Heart, Lung and Blood Institute 2002.
• [20]Carlsohn E, Nystrom J, Karlsson H, Svennerholm AM, Nilsson CL: Characterization of the outer membrane protein profile from disease-related Helicobacter pylori isolates by subcellular fractionation and nano-LC FT-ICR MS analysis. Journal of Proteome Research 2006, 5:3197-3204.
• [21]Thomas PD, Campbell MJ, Kejariwal A, Mi H, Karlak B, Daverman R, Diemer K, Muruganujan A, Narechania A: PANTHER: a library of protein families and subfamilies indexed by function. Genome Research 2003, 13:2129-2141.
• [22]Thomas PD, Kejariwal A, Guo N, Mi H, Campbell MJ, Muruganujan A, Lazareva-Ulitsky B: Applications for protein sequence-function evolution data: mRNA/protein expression analysis and coding SNP scoring tools. Nucleic Acids Research 2006, 34:W645-650.
• [23]Saeed AI, Bhagabati NK, Braisted JC, Liang W, Sharov V, Howe EA, Li J, Thiagarajan M, White JA, Quackenbush J: TM4 microarray software suite. Methods Enzymol 2006, 411:134-193.
• [24]Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J, Klapa M, Currier T, Thiagarajan M, et al.: TM4: a free, open-source system for microarray data management and analysis. Biotechniques 2003, 34:374-378.
• [25]Watanabe Y, Hashimoto Y, Shiratsuchi A, Takizawa T, Nakanishi Y: Augmentation of fatality of influenza in mice by inhibition of phagocytosis. Biochem Biophys Res Commun 2005, 337:881-886.
• [26]Altraja S, Jaama J, Valk E, Altraja A: Changes in the proteome of human bronchial epithelial cells following stimulation with leucotriene E4 and transforming growth factor-beta1. Respirology 2009, 14:39-45.
• [27]Waldburg N, Kahne T, Reisenauer A, Rocken C, Welte T, Buhling F: Clinical proteomics in lung diseases. Pathol Res Pract 2004, 200:147-154.
• [28]Sherry B, Yarlett N, Strupp A, Cerami A: Identification of cyclophilin as a proinflammatory secretory product of lipopolysaccharide-activated macrophages. Proc Natl Acad Sci USA 1992, 89:3511-3515.
• [29]van Diepen A, Brand HK, Sama I, Lambooy LH, van den Heuvel LP, van der Well L, Huynen M, Osterhaus AD, Andeweg AC, Hermans PW: Quantitative proteome profiling of respiratory virus-infected lung epithelial cells. J Proteomics 2010, 73:1680-1693.
• [30]Lakind JS, Holgate ST, Ownby DR, Mansur AH, Helms PJ, Pyatt D, Hays SM: A critical review of the use of Clara cell secretory protein (CC16) as a biomarker of acute or chronic pulmonary effects. Biomarkers 2007, 12:445-467.
• [31]Kang JS, Yoon YD, Ahn JH, Kim SC, Kim KH, Kim HM, Moon EY: B cell-activating factor is a novel diagnosis parameter for asthma. International Archives of Allergy and Immunology 2006, 141:181-188.
• [32]Sutherland AP, Ng LG, Fletcher CA, Shum B, Newton RA, Grey ST, Rolph MS, Mackay F, Mackay CR: BAFF augments certain Th1-associated inflammatory responses. Journal of Immunology 2005, 174:5537-5544.
• [33]Voisin SN, Krakovska O, Matta A, Desouza LV, Romaschin AD, Colgan TJ, Siu KW: Identification of Novel Molecular Targets for Endometrial Cancer Using a Drill-Down LC-MS/MS Approach with iTRAQ. PLoS ONE 2011, 6:e16352.
• [34]Nishimura T, Nomura M, Tojo H, Hamasaki H, Fukuda T, Fujii K, Mikami S, Bando Y, Kato H: Proteomic analysis of laser-microdissected paraffin-embedded tissues: (2) MRM assay for stage-related proteins upon non-metastatic lung adenocarcinoma. J Proteomics 2010, 73:1100-1110.
• [35]Kiesler P, Haynes PA, Shi L, Kao PN, Wysocki VH, Vercelli D: NF45 and NF90 regulate HS4-dependent interleukin-13 transcription in T cells. Journal of Biological Chemistry 2010, 285:8256-8267.
• [36]Hackett TL, Warner SM, Stefanowicz D, Shaheen F, Pechkovsky DV, Murray LA, Argentieri R, Kicic A, Stick SM, Bai TR, Knight DA: Induction of epithelial-mesenchymal transition in primary airway epithelial cells from patients with asthma by transforming growth factor-beta1. American Journal of Respiratory and Critical Care Medicine 2009, 180:122-133.
• [37]Johnson JR, Roos A, Berg T, Nord M, Fuxe J: Chronic respiratory aeroallergen exposure in mice induces epithelial-mesenchymal transition in the large airways. PLoS ONE 2011, 6:e16175.
• [38]Hoshino M, Nakagawa T, Sano Y, Hirai K: Effect of inhaled corticosteroid on an immunoreactive thymus and activation-regulated chemokine expression in the bronchial biopsies from asthmatics. Allergy 2005, 60:317-322.
• [39]Laprise C, Sladek R, Ponton A, Bernier MC, Hudson TJ, Laviolette M: Functional classes of bronchial mucosa genes that are differentially expressed in asthma. BMC Genomics 2004, 5:21. BioMed Central Full Text
• [40]Lotvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, Lemanske RF Jr, Wardlaw AJ, Wenzel SE, Greenberger PA: Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. Journal of Allergy and Clinical Immunology 2011, 127:355-360.
• [41]Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, Wardlaw AJ, Green RH: Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008, 178:218-224.
• [42]Berry M, Morgan A, Shaw DE, Parker D, Green R, Brightling C, Bradding P, Wardlaw AJ, Pavord ID: Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax 2007, 62:1043-1049.
• [43]Barnes PJ: Immunology of asthma and chronic obstructive pulmonary disease. Nature Reviews Immunology 2008, 8:183-192.